REG - IXICO plc - Result of AGM

IXICOAnnouncement

27/01/2023 13:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230127:nRSa1442Oa&default-theme=true

RNS Number : 1442O  IXICO plc  27 January 2023

 

27 January 2023

IXICO plc

("IXICO" or the "Company")

 

Results of AGM

 

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent
insights in neuroscience, announces that all resolutions put forward to its
Annual General Meeting held earlier today were duly passed and the votes cast
were as follows:

 

     RESOLUTION                         VOTES       %       VOTES     %      VOTES       % ISC VOTED  VOTES

FOR
AGAINST
TOTAL
WITHHELD
 1   Reports and Accounts               26,812,002  99.96%  11,472    0.04%  26,823,474  55.48        9,231

 2a  Re-election of Giulio Cerroni      26,821,033  99.96%  11,372    0.04%  26,832,405  55.49        300

 2b  Election of Kate Rogers            26,675,515  99.95%  12,670    0.05%  26,688,185  55.20        144,520
 3   Re-appointment of Auditors         26,808,776  99.94%  16,198    0.06%  26,824,974  55.48        7,731

 4   Allotment of Securities            26,812,002  99.93%  19,681    0.07%  26,831,683  55.49        1,022

 5   * Disapply Pre-Emption Provisions  26,674,807  99.92%  22,559    0.08%  26,697,366  55.22        135,339

* Special Resolution

Please note that a 'vote withheld' is not a vote under English Law and is not
counted in the calculation

of the proportion of the votes 'for' and 'against' a resolution.

 

For further information please contact:

 

 IXICO plc                                         +44 (0)20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                         +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough machine learning AI data
analytics, at scale, through its remote access TrialTracker technology
platform, to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for the Company's pharmaceutical
clients.

 

 

More information is available on www.IXICO.com (http://www.IXICO.com) and
follow us on Twitter @IXICOnews

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGNKOBPBBKDCDB